CAS number 199796-52-6
PubChem 6918473
Jmol-3D images Image 1
Molecular formula C69H81NO15
Molar mass 1164.38 g mol−1
 YesY (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

DHA-paclitaxel (or Taxoprexin) is an investigational drug (from Protarga Inc) made by linking paclitaxel to docosahexaenoic acid (DHA), a fatty acid that is easily taken up by tumor cells; the DHA-paclitaxel “appears not to be cytotoxic until the bond with DHA is cleaved within the cell.”[1] The advantage of DHA-paclitaxel over paclitaxel is DHA-paclitaxel’s ability to carry much higher concentrations of paclitaxel to the cells, which are maintained for longer periods in the tumor cells, thus increasing their action. With increased activity, DHA-paclitaxel, also known as Taxoprexin may have a more successful response in cancer patients than Taxol, and it may be able to treat more types of cancer than Taxol has been able to treat.

Clinical trials

In 2007, a phase II clinical trial reported "modest activity in patients with oesophago-gastric cancer".[2]


  1. ^ Whelan, Jo (2002). "Targeted taxane therapy for cancer". Drug Discovery Today 7 (2): 90–92. doi:10.1016/S1359-6446(01)02149-3. PMID 11790612. 
  2. ^ Jones, RJ; Hawkins, RE; Eatock, MM; Ferry, DR; Eskens, FA; Wilke, H; Evans, TR (2008). "A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma". Cancer chemotherapy and pharmacology 61 (3): 435–41. doi:10.1007/s00280-007-0486-8. PMID 17440725.